We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

38 hedge funds and large institutions have $172M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

93% more capital invested

Capital invested by funds: $88.9M → $172M (+$83M)

27% more funds holding

Funds holding: 30 → 38 (+8)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
38
Holders Change
+8
Holders Change %
+26.67%
% of All Funds
0.61%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
6
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
+$22.4M
2
DM
Deerfield Management
New York
+$11.1M
3
PA
Perceptive Advisors
New York
+$10.9M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$10.3M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.83M

Top Sellers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
-$6.3M
2
O
OrbiMed
New York
-$402K
3
Renaissance Technologies
Renaissance Technologies
New York
-$74K
4
LSA
Leonteq Securities AG
Switzerland
-$70.9K
5
SCM
Sio Capital Management
New York
-$56.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$22.1M +$10.3M +2,625,000 +81%
APM
2
Avidity Partners Management
Texas
$21.5M +$22.4M +5,700,000 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$17.6M +$7.83M +1,989,403 +74%
JJ
4
Johnson & Johnson
New Jersey
$13.8M – – –
O
5
OrbiMed
New York
$11.8M -$402K -102,000 -3%
Canada Pension Plan Investment Board
6
Canada Pension Plan Investment Board
Ontario, Canada
$11.8M – – –
ASP
7
Adams Street Partners
Illinois
$11.1M – – –
DM
8
Deerfield Management
New York
$10.6M +$11.1M +2,823,000 New
PA
9
Perceptive Advisors
New York
$10.4M +$10.9M +2,759,936 New
TGA
10
TPG GP A
Texas
$9.62M – – –
AG
11
Artal Group
Luxembourg
$7.45M +$4.82M +1,225,000 +163%
PBPIA
12
Pivotal bioVenture Partners Investment Advisor
California
$5.88M -$8 -2 -0%
SFM
13
Sphera Funds Management
Israel
$4.84M +$5.05M +1,283,537 New
1832 Asset Management
14
1832 Asset Management
Ontario, Canada
$2.77M – – –
RCM
15
RA Capital Management
Massachusetts
$2.49M – – –
Millennium Management
16
Millennium Management
New York
$1.47M +$1.59M +403,788 New
GTC
17
Ghost Tree Capital
New York
$1.32M +$1.38M +350,000 New
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$1.24M – – –
SCM
19
Sio Capital Management
New York
$928K -$56.7K -14,412 -6%
UOC
20
UBS O'Connor
Illinois
$912K +$953K +242,026 New
Morgan Stanley
21
Morgan Stanley
New York
$446K +$40.5K +10,287 +10%
SI
22
Sofinnova Investments
California
$441K – – –
UBS Group
23
UBS Group
Switzerland
$338K +$107K +27,110 +43%
SAM
24
Sectoral Asset Management
Quebec, Canada
$216K – – –
Two Sigma Investments
25
Two Sigma Investments
New York
$169K +$176K +44,827 New
1
2

FUSN Hedge Fund Activity: Q1 2023 in Review

38 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q1 2023, worth a combined $172M — up 93% from $88.9M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new FUSN positions and 4 closed out — a net gain of 8 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Avidity Partners Management, opening a new position worth an estimated $22.4M. The largest seller was Braidwell, exiting entirely with an estimated $6.3M sold.

  • 38 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q1 2023, up from 30 in Q4 2022.
  • Funds reported $172M of Fusion Pharmaceuticals Inc. Common Shares stock for Q1 2023, up 93% quarter-over-quarter.
  • 12 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q1 2023 and 4 closed out, a net change of +8 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q1 2023 was Avidity Partners Management, an estimated $22.4M added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q1 2023 was Braidwell, an estimated $6.3M sold.

Based on aggregated 13F filings for Q1 2023.